The flurry of drug recalls because of carcinogens has prompted the Food ... to evaluate all products for any risk they might contain nitrosamines. Companies that identify any such risk must ...

The recalled lot may contain high levels of nitrosamines, a carcinogenic compound. The recall is Class II, meaning the health harms associated with taking the tainted medication are likely ...

due to the presence of a potentially carcinogenic chemical. The recall was initiated on October 10, 2024, after the discovery of N-nitroso-duloxetine, a nitrosamine impurity, in the medication.

In 2018, the FDA began an investigation into nitrosamine impurities in drugs that led to high-profile recalls for heartburn ...

Ontario’s highest court affirmed the principle that a certifiable tort claim requires a plaintiff to provide some basis in fact for ...

Lupin Pharmaceuticals is recalling four lots of quinapril tablets because of unacceptable levels of the nitrosamine impurity, N-nitroso-quinapril, a potential carcinogen. Nitrosamines "may ...

As federal regulators increase their focus on pharmaceuticals with unacceptable levels of the probable carcinogen nitrosamine, a McHenry County drug delivery company is working on packaging that ...

Are they good or bad? After all, they can form nitrosamines, recognized carcinogens. A new study uses the metaphor of Dr. Jekyll and Mr. Hyde to separate science truth from science fiction. Here’s ...

The capsules may contain a chemical compound called N-nitroso-duloxetine – known to include the carcinogenic substance nitrosamine. The compound is toxic if swallowed and is suspected of ...